Shares of Enliven Therapeutics (ELVN) plummeted 5.22% during Friday's intraday trading session, reflecting investor concerns following an analyst's downward revision of the company's price target.
The significant drop in share price came after JonesResearch analyst Soumit Roy lowered the firm's price target on Enliven from $36 to $27. Despite the reduction, Roy maintained a Buy rating on the stock, suggesting continued confidence in the company's long-term prospects despite near-term headwinds.
While the exact reasons for the lowered price target were not detailed in the available information, such revisions often stem from changes in a company's financial outlook, market conditions, or sector-specific challenges. Investors appear to be reacting cautiously to this adjustment, leading to the sharp decline in Enliven's stock price. However, the maintained Buy rating indicates that JonesResearch still sees potential upside for the stock, albeit from a lower base.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。